FEEDS
Pfizer Announces European Union Approval of a New Form of Lipitor (atorvastatin) for Use in Children
New York, July 6, 2010 (ots/PRNewswire) - Pfizer Inc. announced it has received European Commission approval of a new chewable form of Lipitor (atorvastatin calcium) suitable for use in children aged 10 or older with high levels of LDL ("bad") ... weiter zur Meldung von Pfizer Inc.
Football Stars Unite to Tackle Back Pain
Rome, June 8, 2010 (ots/PRNewswire) - UK Premiership footballer Rory Delap, renowned for his devastating throw-in, has joined forces with a number of football heroes across Europe to support 'Back in Play', a European wide campaign to reach young ... weiter zur Meldung von Pfizer Inc.
Europeans Face a Painful Truth on First Ever Neuropathic Pain Day - October 13
London (ots/PRNewswire) - - Not for UK Journalists - New Survey Reveals Widespread Ignorance of Debilitating Pain Condition Affecting Millions of Europeans Alarmingly, nearly sixty per cent of Europeans have never heard of neuropathic pain (NeP), ... weiter zur Meldung von Pfizer Inc.
Maraviroc, das neuartige Medikament von Pfizer gegen HIV, senkt signifikant die Viruslast bei der Kombinationsbehandlung von unterschiedlich vorbehandelten Patienten
Los Angeles (ots/PRNewswire) - - Entscheidende Ergebnisse auf der 14. Conference on Retroviruses and Opportunistic Infections (CROI)vorgestellt - Beschleunigte Prüfung von Maraviroc in den USA und Europa Auf der in dieser Woche ... weiter zur Meldung von Pfizer Inc.
Danish Court Issues Preliminary Injunction That Prohibits Sale of Generic Lipitor Product
New York (ots/PRNewswire) - Pfizer Inc said today that a Danish court has granted a preliminary injunction against Nomeco A/S -- the largest pharmaceutical wholesaler in Denmark -- that prohibits the sale of a generic version of Lipitor by ... weiter zur Meldung von Pfizer Inc.
Celebrex Label Extended for New Use in Europe
New York (ots/PRNewswire) - - Celebrex to be Available in Europe for the Treatment of Ankylosing Spondylitis, a Debilitating Form of Arthritis Pfizer Inc announced today that 17 European countries agreed to extend the Celebrex (celecoxib ... weiter zur Meldung von Pfizer Inc.
Pfizer's Maraviroc to Receive Accelerated Regulatory Reviews in the U.S. and Europe
New York (ots/PRNewswire) - - If Approved, Maraviroc will be the First in a New Class of Medications Available for HIV Treatment Pfizer announced today that marketing authorization applications for maraviroc will receive accelerated ... weiter zur Meldung von Pfizer Inc.
Pfizer's Sutent(R) Is Granted Full Marketing Authorization for First-Line Use in Advanced Kidney Cancer in the European Union
New York (ots/PRNewswire) - - Full marketing authorization and extension of indication to first-line treatment of advanced and/or metastatic renal cell carcinoma (MRCC) - First multiple receptor tyrosine kinase inhibitor to be approved in ... weiter zur Meldung von Pfizer Inc.
Das Gesundheitswesen in Europa nachhaltig finanzieren: Was bekommen wir für unser Geld?
Brüssel (ots/PRNewswire) - - Die Bevölkerungsstruktur ist alarmierend. Das Ausmass des Problems: Bis 2050 werden Schätzungen zufolge Menschen über 60 ein Drittel der europäischen Bevölkerung ausmachen [1] - die Gruppe der über 80jährigen soll ... weiter zur Meldung von Pfizer Inc.
Pfizer Announces Plans to Establish Expanded Access Program for Maraviroc, Investigational HIV CCR5 Antagonist
New York (ots/PRNewswire) - - Broad Access Program for Patients with Limited Available Treatment Options Pfizer announced today that it plans to establish a multi-national Expanded Access Program (EAP) to make the investigational ... weiter zur Meldung von Pfizer Inc.
Results of New Combined Analysis Concludes Patients at Risk for Glaucoma Will Benefit From Risk Assessment Tool
Las Vegas, November 15 (ots/PRNewswire) - - New data confirm a five-year risk assessment tool will help ophthalmologists better predict which patients have an increased risk of developing glaucoma - Analysis finds that ... weiter zur Meldung von Pfizer Inc.
European Patent Office Supports Validity of Lipitor Patent
New York (ots/PRNewswire) - - Madrid, Spain Court of Appeal Confirms Pfizer's Patent Claims Pfizer Inc said today that the European Patent Office (EPO) has issued an opinion upholding, in its entirety, the company's calcium salt patent ... weiter zur Meldung von Pfizer Inc.
Pfizer Assists World Health Organization in Search for New Treatments Against Diseases of the Developing World
New York (ots/PRNewswire) - - Company Opens its Compound Library to Help Search for New Anti-Parasitic Medicines Pfizer announced today collaboration that gives access to its library of medicinal compounds -- the world's largest -- and ... weiter zur Meldung von Pfizer Inc.
Austrian Patent Office Rules in Pfizer's Favor, Ranbaxy Product Would Infringe Basic Lipitor Patent
New York (ots/PRNewswire) - Pfizer said today that the Austrian Patent Office has ruled that a claim in the company's basic patent covering the use of atorvastatin, the active ingredient in Lipitor, would be infringed by generic manufacturer ... weiter zur Meldung von Pfizer Inc.
Pfizer's Lyrica(R) Approved in Europe for Difficult-to-Treat Nerve Pain
New York (ots/PRNewswire) - - Lyrica's neuropathic pain indication broadened to include central nerve pain; Central nerve pain is associated with conditions such as spinal cord injury, stroke, and multiple sclerosis - A ... weiter zur Meldung von Pfizer Inc.
Globale Koalition von Diabetes-Experten ruft zu kompromissloser Kontrolle von Diabetes auf, um eine verheerende und kostspielige globale Belastung zu vermeiden
EASD - KOPENHAGEN, September 15 (ots/PRNewswire) - - Globaler Handlungsaufruf von Diabetes-Experten aus Europa, Lateinamerika, Asien, den USA, Kanada und Australien - Diabetes-Experte: - Wir müssen die Kontrolle von Diabetes ... weiter zur Meldung von Pfizer Inc.
Exubera Effective in Diabetes Patients who Have Respiratory Infections or are Exposed to Passive Cigarette Smoke, New Analyses Show
Copenhagen, Denmark (ots/PRNewswire) - - Twice as Many People With Uncontrolled Type 2 Diabetes Would Accept Insulin if Offered Exubera, Even in Countries Where Pens are Commonly Used, Additional Study Shows - Patients With ... weiter zur Meldung von Pfizer Inc.
Niederländisches Gericht bestätigt grundlegendes Lipitor-Patent und unterbindet Markteinführung von Ranbaxy vor November 2011
New York (ots/PRNewswire) - Pfizer Inc gab heute bekannt, dass das Amtsgericht von Den Haag in den Niederlanden verfügt hat, dass das grundlegende Patent für Atorvastatin, dem aktiven Wirkstoff von Lipitor, durch das Konkurrenzprodukt des ... weiter zur Meldung von Pfizer Inc.
Exubera Hailed as Innovation In Prestigious European and American Awards
New York (ots/PRNewswire) - - WSJ/Professor Pedro Nueno: "The drug could encourage diabetes sufferers to get treatment earlier and more often. This has such a tremendous advantage for a huge number of people worldwide. It is a real ... weiter zur Meldung von Pfizer Inc.
Auf Amlodipin basierende Behandlungsstrategie zur Blutdrucksenkung senkt das Risiko der Neuentstehung von Diabetes bei Bluthochdruckpatienten um mehr als ein Drittel
Barcelona, Spanien (ots/PRNewswire) - - Herausgegeben im Namen des Lenkunksauschusses der ASCOT-Studie (Anglo-Scandinavian Cardiac Outcomes Trial) Für eine auf dem Kalziumantagonisten Amlodipin basierende Behandlungsstrategie konnte ... weiter zur Meldung von Pfizer Inc.
Lipitor More Effective Than Simvastatin in Cutting Risk of Additional Heart Attacks in Patients Who Had a Recent Heart Attack, New Data Suggests
New York (ots/PRNewswire) - - Heart Disease Patients who Were at a Very High Risk for Having a Second Heart Attack and Took Lipitor 80mg Had a 46 Percent Reduction in the Risk of Experiencing Additional Heart Attacks Compared With Patients ... weiter zur Meldung von Pfizer Inc.
New Lipitor Data Published in The Lancet
New York (ots/PRNewswire) - - Lipitor Reduces Risk of Major Cardiovascular Events Such as Heart Attacks in People With Heart Disease and With a Cluster of Other Major Cardiovascular Risk Factors, Often Referred to as Metabolic Syndrome, New ... weiter zur Meldung von Pfizer Inc.
Pfizer's Champix(R) Receives Positive Opinion From CHMP for the Treatment of Smoking Cessation
New York (ots/PRNewswire) - - More Than 1.2 Million Europeans Die of Smoking-Related Diseases Each Year; An Estimated US$500 Billion in Global Health-Related Costs by 2010 - Medical Expert: 'Helping smokers quit is one of the ... weiter zur Meldung von Pfizer Inc.
Kommission der Europäischen Gemeinschaft erteilt bedingte Marktzulassung für Pfizers Sutent(R)
New York (ots/PRNewswire) - Wie die Pfizer Inc heute mitteilte, erhielt Sutent(R) (Sunitinib Malate) die europäische, bedingte Marktzulassung für fortgeschrittene und/oder metastasierende Nierenzellkarzinome (mRCC), eine Art ... weiter zur Meldung von Pfizer Inc.
Sutent von Pfizer erhält positive Beurteilung in der EU für zwei schwer behandelbare, fortgeschrittene Krebsarten
New York (ots/PRNewswire) - Pfizer Inc verlautbarte heute, dass das Committee for Human Medicinal Products (CHMP) eine positive Beurteilung abgegeben hat. Es hat eine bedingte Marktzulassung für Pfizers neues Krebsmedikament Sutent (Sunitinib ... weiter zur Meldung von Pfizer Inc.
